DISCUSSION
Dapsone (4,4'-diaminodiphenyl sulphone) is known to suppress inflammatory conditions associated with neutrophils. At the cellular level it is considered to inhibit myeloperoxidase-catalysed reactions of the neutrophils (4) . It has been postulated that the drug inhibits calcium-dependent functions of the neutrophils, including release of tissue-damaging oxidants and proteases in the affected skin (5) , and that it inhibits the process by which neutrophils leave the circulation and migrate to lesional sites (6) . Furthermore, it is thought to inhibit adherence of neutrophils to the basement membrane zone antibodies, possibly by direct effect on the antibodies (7). Dapsone is eliminated by oxidation predominantly by cytochrome P450 3A4 (8) . It has been postulated that the oxidation is by myeloperoxidase to hydroxylamine, which may be responsible for the pharmacological effects as well as the side-effects of methaemoglobinaemia and haemolysis caused by the drug (9) .
Control of anaemia with darbepoetin-alpha has been reported in association with cancer chemotherapy (10) Apart from that field, and to the best of our knowledge, this is the first time darbepoetin-alpha has been used successfully to control a drug-induced anaemia. It has, however, been discussed in the literature whether the drug may be effective in treating anti-viral induced anaemia (11) . Darbepoetin-alpha has been used in the treatment of renal failure (12) , to control anaemia due to inflammatory bowel disease (3) and in diabetes-induced anaemia (13) .
Linear IgA disease is a rare acquired autoimmune bullous disorder. It has a variable course and may last for years, with spontaneous resolution in some cases. Reported remission rates range from 10% to 60% (14) . When it is manifested simply as oropharyngeal ulceration and desquamative gingivitis, it may, unfortunately, result in a diagnostic and treatment delay (15) . Long delay may result in a serious ophthalmological outcome, as the disease may lead to blindness. We suggest that physicians consider the option of controlling dapsone-induced anaemia with darbepoetin-alpha before considering treatment with stronger immunosuppressive medications with increased mortality rates. We feel that such a choice might have a trivial outcome in our case, considering the age of the patient. 
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